This document discusses gene therapy, which involves introducing a normal functional gene into a patient's cells to correct a genetic disorder. It provides examples of genetic disorders that may be candidates for gene therapy, such as Down syndrome, cystic fibrosis, and sickle cell anemia. The document outlines the mechanisms of gene therapy, including using viral vectors to deliver therapeutic genes to targeted cells. Requirements for effective gene therapy and different methods like ex vivo and in vivo approaches are also summarized. Potential advantages include providing treatment for previously untreatable genetic diseases, while disadvantages include high costs and safety concerns.
Gene therapy is emerging branch of healthcare, we can see that with the possible development it has potential to treat multiple genetic as well as other conditions and disease
hope young scholar can find this presentation useful and i am open to any suggestions
Surviving animals produced by nuclear transfer are healthy.
There, is a substantial loss of individual before and after birth some of the cloned animals display abnormalities.
Abnormlities such as increased birth weight.
Dna methylation and histone modification of the original donor cell is inappropriate maintained in the cells of the recipient animals.
INVIVO:
The direct delivery of the therapeutic gene into the target cells of a particular tissue.
Genes are changed in cells when the cells are still in the body.
These include liver, muscle, skin, spleen, lung, brain and blood cells.
Carried out by viral and non viral vector system
EXVIVO:
Cells are modified outside the body and then transplanted back in again.
SCID is a inherited immune disorder associated with T-lymphocyte and B-lymphocytes dysfunction.
Gene encodes for adenosine deaminase.
The patients of SCID(lacking ADA) suffer from infectious diseases and die at an young age.
Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches (see video: 'Gene Therapy a new tool to cure human diseases'). A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy, but it has been used with some success.
Advances in biochemistry and molecular biology have helped to understand the genetic basis of inherited diseases.
Gene therapy was once considered a fantasy (imaginary).
It was a dream of the researchers to replace the defective genes with good ones and cure the genetic disorders.
INTRODUCTION OF GENE THERAPY, HISTORY OF GENE THERAPY, Process of gene therapy, Methods of gene therapy, Ex vivo gene therapy , In Vivo Gene Therapy , Uses of gene therapy, Target sites for Gene Therapy , Vectors for gene therapy , Viral Vectors, Non Viral Vectors,
This presentation focuses on the science of Gene Therapy, the techniques of germ-line and somatic gene therapy and the mechanism of curing diseases and disorders using gene therapy. The presentation starts by discussing some common basic terms from genetics and moves on to the historical development of gene therapy techniques in chronological order. The different types of gene therapy techniques and their mechanisms have been discussed in detail subsequently. In concluding slides, some commercially available gene therapy products are mentioned and challenges of gene-therapy techniques have been highlighted.
Gene therapy is emerging branch of healthcare, we can see that with the possible development it has potential to treat multiple genetic as well as other conditions and disease
hope young scholar can find this presentation useful and i am open to any suggestions
Surviving animals produced by nuclear transfer are healthy.
There, is a substantial loss of individual before and after birth some of the cloned animals display abnormalities.
Abnormlities such as increased birth weight.
Dna methylation and histone modification of the original donor cell is inappropriate maintained in the cells of the recipient animals.
INVIVO:
The direct delivery of the therapeutic gene into the target cells of a particular tissue.
Genes are changed in cells when the cells are still in the body.
These include liver, muscle, skin, spleen, lung, brain and blood cells.
Carried out by viral and non viral vector system
EXVIVO:
Cells are modified outside the body and then transplanted back in again.
SCID is a inherited immune disorder associated with T-lymphocyte and B-lymphocytes dysfunction.
Gene encodes for adenosine deaminase.
The patients of SCID(lacking ADA) suffer from infectious diseases and die at an young age.
Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches (see video: 'Gene Therapy a new tool to cure human diseases'). A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy, but it has been used with some success.
Advances in biochemistry and molecular biology have helped to understand the genetic basis of inherited diseases.
Gene therapy was once considered a fantasy (imaginary).
It was a dream of the researchers to replace the defective genes with good ones and cure the genetic disorders.
INTRODUCTION OF GENE THERAPY, HISTORY OF GENE THERAPY, Process of gene therapy, Methods of gene therapy, Ex vivo gene therapy , In Vivo Gene Therapy , Uses of gene therapy, Target sites for Gene Therapy , Vectors for gene therapy , Viral Vectors, Non Viral Vectors,
This presentation focuses on the science of Gene Therapy, the techniques of germ-line and somatic gene therapy and the mechanism of curing diseases and disorders using gene therapy. The presentation starts by discussing some common basic terms from genetics and moves on to the historical development of gene therapy techniques in chronological order. The different types of gene therapy techniques and their mechanisms have been discussed in detail subsequently. In concluding slides, some commercially available gene therapy products are mentioned and challenges of gene-therapy techniques have been highlighted.
Definition, Gene therapy, types of gene therapy, germline gene therapy, somatic cell gene therapy, basic process of gene therapy and potential targets for gene therapy.
NUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptxPRAMESHPANWAR1
Name of the title: Nucleic Acid-Based Therapeutic Delivery System.
It includes information about nucleic acid, gene therapy, and its type, a method to deliver the desired DNA, i.e., vectors and their types, with proper examples and diagrams, and how these things help in delivering a nucleic acid-based therapeutic drug delivery system.
Gene therapy is the process of inserting genes into cells to prevent, treat or cure wide range of diseases. Gene therapy primarily involves genetic manipulations in animals or humans to correct a disease. Gene augmentation therapy: a DNA is inserted into the Genome to replace the missing gene product.Gene inhibition therapy: the antisense gene inhibits the expression of the dominant gene.
These slide include gene therapy defines with their types like Germ line gene therapy,Somatic gene therapy.
with Need of Gene therapy
strategies of gene therapy
Methods of Gene transfer & with
GENE THERAPY FOR INHERITED DISORDERS
Introduction:
RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is an important biological process for modulating eukaryotic gene expression.
It is highly conserved process of posttranscriptional gene silencing by which double stranded RNA (dsRNA) causes sequence-specific degradation of mRNA sequences.
dsRNA-induced gene silencing (RNAi) is reported in a wide range of eukaryotes ranging from worms, insects, mammals and plants.
This process mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes.
What are small ncRNAs?
micro RNA (miRNA)
short interfering RNA (siRNA)
Properties of small non-coding RNA:
Involved in silencing mRNA transcripts.
Called “small” because they are usually only about 21-24 nucleotides long.
Synthesized by first cutting up longer precursor sequences (like the 61nt one that Lee discovered).
Silence an mRNA by base pairing with some sequence on the mRNA.
Discovery of siRNA?
The first small RNA:
In 1993 Rosalind Lee (Victor Ambros lab) was studying a non- coding gene in C. elegans, lin-4, that was involved in silencing of another gene, lin-14, at the appropriate time in the
development of the worm C. elegans.
Two small transcripts of lin-4 (22nt and 61nt) were found to be complementary to a sequence in the 3' UTR of lin-14.
Because lin-4 encoded no protein, she deduced that it must be these transcripts that are causing the silencing by RNA-RNA interactions.
Types of RNAi ( non coding RNA)
MiRNA
Length (23-25 nt)
Trans acting
Binds with target MRNA in mismatch
Translation inhibition
Si RNA
Length 21 nt.
Cis acting
Bind with target Mrna in perfect complementary sequence
Piwi-RNA
Length ; 25 to 36 nt.
Expressed in Germ Cells
Regulates trnasposomes activity
MECHANISM OF RNAI:
First the double-stranded RNA teams up with a protein complex named Dicer, which cuts the long RNA into short pieces.
Then another protein complex called RISC (RNA-induced silencing complex) discards one of the two RNA strands.
The RISC-docked, single-stranded RNA then pairs with the homologous mRNA and destroys it.
THE RISC COMPLEX:
RISC is large(>500kD) RNA multi- protein Binding complex which triggers MRNA degradation in response to MRNA
Unwinding of double stranded Si RNA by ATP independent Helicase
Active component of RISC is Ago proteins( ENDONUCLEASE) which cleave target MRNA.
DICER: endonuclease (RNase Family III)
Argonaute: Central Component of the RNA-Induced Silencing Complex (RISC)
One strand of the dsRNA produced by Dicer is retained in the RISC complex in association with Argonaute
ARGONAUTE PROTEIN :
1.PAZ(PIWI/Argonaute/ Zwille)- Recognition of target MRNA
2.PIWI (p-element induced wimpy Testis)- breaks Phosphodiester bond of mRNA.)RNAse H activity.
MiRNA:
The Double-stranded RNAs are naturally produced in eukaryotic cells during development, and they have a key role in regulating gene expression .
This pdf is about the Schizophrenia.
For more details visit on YouTube; @SELF-EXPLANATORY;
https://www.youtube.com/channel/UCAiarMZDNhe1A3Rnpr_WkzA/videos
Thanks...!
Cancer cell metabolism: special Reference to Lactate PathwayAADYARAJPANDEY1
Normal Cell Metabolism:
Cellular respiration describes the series of steps that cells use to break down sugar and other chemicals to get the energy we need to function.
Energy is stored in the bonds of glucose and when glucose is broken down, much of that energy is released.
Cell utilize energy in the form of ATP.
The first step of respiration is called glycolysis. In a series of steps, glycolysis breaks glucose into two smaller molecules - a chemical called pyruvate. A small amount of ATP is formed during this process.
Most healthy cells continue the breakdown in a second process, called the Kreb's cycle. The Kreb's cycle allows cells to “burn” the pyruvates made in glycolysis to get more ATP.
The last step in the breakdown of glucose is called oxidative phosphorylation (Ox-Phos).
It takes place in specialized cell structures called mitochondria. This process produces a large amount of ATP. Importantly, cells need oxygen to complete oxidative phosphorylation.
If a cell completes only glycolysis, only 2 molecules of ATP are made per glucose. However, if the cell completes the entire respiration process (glycolysis - Kreb's - oxidative phosphorylation), about 36 molecules of ATP are created, giving it much more energy to use.
IN CANCER CELL:
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
introduction to WARBERG PHENOMENA:
WARBURG EFFECT Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside.
Otto Heinrich Warburg (; 8 October 1883 – 1 August 1970) In 1931 was awarded the Nobel Prize in Physiology for his "discovery of the nature and mode of action of the respiratory enzyme.
WARNBURG EFFECT : cancer cells under aerobic (well-oxygenated) conditions to metabolize glucose to lactate (aerobic glycolysis) is known as the Warburg effect. Warburg made the observation that tumor slices consume glucose and secrete lactate at a higher rate than normal tissues.
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...Scintica Instrumentation
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes.
In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
Professional air quality monitoring systems provide immediate, on-site data for analysis, compliance, and decision-making.
Monitor common gases, weather parameters, particulates.
The increased availability of biomedical data, particularly in the public domain, offers the opportunity to better understand human health and to develop effective therapeutics for a wide range of unmet medical needs. However, data scientists remain stymied by the fact that data remain hard to find and to productively reuse because data and their metadata i) are wholly inaccessible, ii) are in non-standard or incompatible representations, iii) do not conform to community standards, and iv) have unclear or highly restricted terms and conditions that preclude legitimate reuse. These limitations require a rethink on data can be made machine and AI-ready - the key motivation behind the FAIR Guiding Principles. Concurrently, while recent efforts have explored the use of deep learning to fuse disparate data into predictive models for a wide range of biomedical applications, these models often fail even when the correct answer is already known, and fail to explain individual predictions in terms that data scientists can appreciate. These limitations suggest that new methods to produce practical artificial intelligence are still needed.
In this talk, I will discuss our work in (1) building an integrative knowledge infrastructure to prepare FAIR and "AI-ready" data and services along with (2) neurosymbolic AI methods to improve the quality of predictions and to generate plausible explanations. Attention is given to standards, platforms, and methods to wrangle knowledge into simple, but effective semantic and latent representations, and to make these available into standards-compliant and discoverable interfaces that can be used in model building, validation, and explanation. Our work, and those of others in the field, creates a baseline for building trustworthy and easy to deploy AI models in biomedicine.
Bio
Dr. Michel Dumontier is the Distinguished Professor of Data Science at Maastricht University, founder and executive director of the Institute of Data Science, and co-founder of the FAIR (Findable, Accessible, Interoperable and Reusable) data principles. His research explores socio-technological approaches for responsible discovery science, which includes collaborative multi-modal knowledge graphs, privacy-preserving distributed data mining, and AI methods for drug discovery and personalized medicine. His work is supported through the Dutch National Research Agenda, the Netherlands Organisation for Scientific Research, Horizon Europe, the European Open Science Cloud, the US National Institutes of Health, and a Marie-Curie Innovative Training Network. He is the editor-in-chief for the journal Data Science and is internationally recognized for his contributions in bioinformatics, biomedical informatics, and semantic technologies including ontologies and linked data.
2. GENETIC DISORDER
A genetic disorder is a disease that is caused by
an abnormality in an individual's DNA.
Abnormalities can range from a small mutation
in a single gene to the addition or subtraction of
an entire chromosome or set of chromosomes
4. GENE THERAPY
• Definition: the introduction of a normal
functional gene into cell of patient which
contains the defective allele of concerned gene
with the objective of correcting a genetic
disorder or an acquired disorder.
• Gene therapy is a method where an absent or
faulty gene is replaced by a working gene in
order to make the correct enzyme or protein
and eliminate the cause of diseases
5. HOW GENE THERAPY WORKS
• The genes will be contained in vector carriers
that seek out targeted cells
• – such as tumor cells – and bypass all others
• When the carriers reach their targets, they will
unload their genetic material
• and give rise to a helpful protein
8. VECTORS
• Are the vehicles used to carry the beneficial genetic material to
the mutated cells
• A completely reliable, safe and efficient vector is not yet
available
• A perfect vector would target specific cell types, insert their
genetic information into a safe site in the genome, and be
regulated by normal physiological signals
9. General Principles
• The various approaches to gene therapy
includes
• Addition of normal genes to replace the
function of a mutant gene.
• Replacement of mutant gene sequence of
normal gene sequences.
• By construction of novel gene.
• By altering gene regulation.
10. MECHANISM OF GENE
THERAPY
• The general mechanism of gene therapy involves basic steps
-
• 1. The approximately 100000 genes in a cell encode the
many proteins used by the body.
• 2. Each gene is a segment of the DNA molecule in a
chromosome.
• 3. Researchers used a virus whose DNA naturally inserts
into human DNA.
• 4. They splice a human gene into the viral genome.
• 5. Place the modified virus into the human respiratory tract.
• 6. The viruses invade the cells, carrying along the gene. The
latter encodes proteins to provide relief from the disease.
11. HISTORY AND DEVELOPMENT
OF GENE THERAPY
1960: The concepts of Gene Therapy was introduced
1970: Friedmann and Roblin author of a paper in Science titled
"Gene therapy for human genetic disease?” cite the first
attempt to perform gene therapy.
1990: The first approved gene therapy case at the National
Institute of Health, U.K. It was performed on a four year old
girl named Ashanti DaSilva. It was a treatment for a genetic
defect that left her with an immune system deficiency.
New gene therapy approach repairs errors in messenger RNA
derived from defective genes. This technique has the potential
to treat the blood disorder Thalassaemia, Cystic fibrosis, and
some cancers
Sickle cell disease is successfully treated in mice
13. REQUIREMENT FOR GENE
THERAPY
There are several requirements for a gene
therapy protocol to be effective. Firstly, the gene
defects itself will have been characterized and
the gene cloned and available in a form suitable
for use in a clinical program. Secondly, there
must be a system available for getting a gene
into a correct site in the patient. A large number
of approaches have been tried for effective
transfer of gene to appropriate target site.
15. General principles
• The various approaches to gene therapy
includes-
• Addition of normal genes to replace the
function of a mutant gene.
• Replacement of mutant gene sequence of
normal gene sequences.
• By construction of novel gene.
• By altering gene regulation.
17. Methods
• The transfer and expression of recombinant gene
in various target cells in gene therapy requires.
• Efficient transformation of a larger number of
primary cells, specific for various cells and organs
and
• Transformation be carried without causing any
alteration in the structure of the recombinant gene
of target cell.
• The methods employed are DNA mediated and
viral mediated.
18. Applications
• Any deviation in the normal functioning of a cell
or tissues of a particular organ are theoretically
amenable to correction by somatic gene therapy.
• The potential of a gene therapy to alter the
phenotype of a given disease may differentially be
affected by variables such as the cellular location
of gene product, level of expression, degree of
regulation, and number of cells transformed with
normal genes.
19. • Many disorders cause abnormalities during
early development which may not be reversed
by subsequent gene therapy i.e.
phenylketonuria.
20. HOW IT WORKS??
Used harmless viruses enable access to the cells
beneath the retinas of patients By using a very
fine needle , safe in an extremely fragile tissue
and can improve vision in a condition previously
considered wholly untreatable.
21. ADVANTAGES OF GENE
THERAPY
• Give a chance of a normal life to baby born
with genetic disease.
• Give hope of healthy life to cancer patient.
• For certain disease that do not have any cure
except gene therapy, it could save many lives
22. DISADVANTAGES OF
GENE THERAPY
• The genetic testing, screening and research in
finding the availability of certain gene is very
controversy.
• May increase rate of abortion if prenatal test
regarding baby with genetic disease is done.
• The cost is very high and the patient might need
an insurance to cover the treatment.
• Cosmetic industry may monopolized this gene
therapy, if it is used in enhancing beauty and in
vanishing the aging effect, rather than used for
treatment of a disease.